BIND Biosciences Inc.
This article was originally published in Start Up
Executive Summary
BIND Biosciences generates nanoparticles with unique targeting agents that allow them to home in on cancerous cells with deadly precision. Because it's impossible to mathematically design the optimal particle, BIND scientists have created large combinatorial libraries of nanoparticles with different biophysical and chemical properties.
You may also be interested in...
In Oncology Drug Boom, Can Next-Gen Cytotoxics Fit In?
The drug industry has placed a bull's eye on the field of oncology as a key therapeutic area, but not all oncology players are created equal.
FDA Seeks Public Input To Develop Guidance For Nanotechnology In Pharmaceuticals
Sept. 8 public meeting requests input on safety, efficacy points to consider for using nanotech in drugs, biologics.
Liquidia Technologies Inc.
Liquidia Technologies is developing nanoparticles whose size, shape, particle cargo, and target specificity can be exquisitely controlled. In order to create its particles, Liquidia borrows fabrication methods originally developed by the electronics industry. I